XML 18 R5.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Operating activities:    
Net loss $ (74,827) $ (120,247)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation expense 21,847 21,268
Depreciation and amortization 1,457 1,392
Amortization of debt issuance costs 103 100
(Accretion of discount) amortization of premium on short-term investments (835) 93
Impairment of property and equipment 309 88
Loss on disposal of property and equipment 23 96
Change in operating assets and liabilities:    
Accounts receivable (24,644) (4,804)
Inventory 9,950 (12,936)
Prepaid expenses and other assets 10,369 4,098
Accounts payable (1,268) 10,001
Accrued clinical and manufacturing liabilities (4,587) 19,954
Accrued payroll and employee liabilities (3,560) 1,060
Other accrued and other non-current liabilities 13,598 7,525
Net cash used in operating activities (52,065) (72,312)
Investing activities:    
Purchases of short-term investments (28,381) (58,945)
Maturities and sales of short-term investments 78,935 90,957
Purchases of property and equipment (502) (1,366)
Proceeds from the sale of property and equipment   56
Net cash provided by investing activities 50,052 30,702
Financing activities:    
Payments for stock issued under the equity incentive plan (593) (1,094)
Proceeds from purchases under the employee stock purchase plan 704 772
Net cash provided by (used in) financing activities 111 (322)
Net decrease in cash and cash equivalents (1,902) (41,932)
Cash and cash equivalents at beginning of year 15,364 90,541
Cash and cash equivalents at end of period 13,462 48,609
Supplemental disclosure of cash flow information:    
Interest paid $ 1,125 $ 1,125